therefore be regarded as an internationally recognised global player and that such status entails additional social responsibility for India; 46. Stresses the need also for the EU to assist India in combating poverty and in attaining its development targets generally; also emphasises the need for the EU to cooperate with India over a wide range of issues including development policy, governance, environmental sustainability and social and economic cohesion; 47. Stresses, moreover, that the EU should consider it important to encourage and support India in regard to the implementation or continuing adoption of international labour standards, in particular through the comprehensive ratification and practical application of the ILO Conventions and, in particular, given the need to combat child labour, which continues to be a major problem in India today, the Convention concerning Minimum Age for Admission to Employment (Minimum Age Convention (C138)); 48. Welcomes the EUR 1 800 million Airbus deal, concluded during the EU-India Business Summit of 7 September 2005, which is a sign of developing bilateral relations and confirmed the success of the European consortium; Development 49. Is seriously concerned at the spread of AIDS in the country, which could become an epidemic in the region unless it is firmly tackled, and calls on the Indian Government to declare a firm commitment to tackling this problem as a priority, exchanging information and seeking to develop common strategies with other countries affected; 50. Understands that the laws on intellectual property rights recently adopted by the Indian Parliament may have adverse effects on the production capacity of the Indian pharmaceutical industry, which has been a source of reliable and affordable medicines, particularly for AIDS, for many patients world-wide; therefore strongly believes that the law should allow derogations for medicines which are of public interest, such as those used to combat, inter alia, AIDS, cancer, malaria, tuberculosis and hepatitis; believes that access to reliable and affordable medicines, in particular for AIDS, is critical; calls upon the Indian authorities to ensure that international standards of animal welfare are applied in the use of live animals in scientific experiments and that such experiments are minimised and alternatives found; 51. Points out that half of the patients who take antiviral medicines in poor countries are using medication produced in India; calls on the EU to support India in further implementing its intellectual property laws in a manner that will avoid barriers to the production, marketing and export of essential medicines and, in so doing, create an environment that will continue to encourage and facilitate investment by the Indian generic manufacturing industry in providing affordable essential medicines for developing countries; 52. Recalls that the WTO allows such derogations and that the Doha Declaration on TRIPS still applies, which states that "the Agreement can and should be interpreted and implemented in a manner supportive of WTO members" right to protect public health and, in particular, to promote access to medicines for all"; 53. Encourages the Commission and India to work together, on the basis of permanent and continuous contacts, to push the Doha Development Agenda (DDA) forward to a